Andrew Lo

CIK: 0001679076

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)5 (62.5%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (37.5%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

BBIO

BridgeBio Pharma, Inc.

Director

ABCL

AbCellera Biologics Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (8 total)

BBIO
BridgeBio Pharma, Inc.
Jun 22, 2026
Award(A)
Direct
4K shares-
BBIO
BridgeBio Pharma, Inc.
Nov 18, 2025
Sale(S)
Indirect
24K shares at avg. $65.23$1.6M
BBIO
BridgeBio Pharma, Inc.
Nov 18, 2025
Sale(S)
Indirect
31K shares at avg. $66.05$2.0M
BBIO
BridgeBio Pharma, Inc.
Nov 17, 2025
Sale(S)
Direct
36.8K shares at avg. $66.63$2.5M
BBIO
BridgeBio Pharma, Inc.
Nov 17, 2025
Sale(S)
Direct
3.8K shares at avg. $67.06$255K
BBIO
BridgeBio Pharma, Inc.
Jun 20, 2025
Award(A)
Direct
6.6K shares-
ABCL
AbCellera Biologics Inc.
Jun 12, 2025
Award(A)
Share option (right to buy)
Direct
238.9K shares-
BBIO
BridgeBio Pharma, Inc.
May 2, 2025
Sale(S)
Indirect
100K shares at avg. $38.50$3.8M

		Type	Shares	Price		Ownership
Jun 22, 2026	BBIO BridgeBio Pharma, Inc.	Award(A)	3,990	-	$0	Direct
Nov 18, 2025	BBIO BridgeBio Pharma, Inc.	Sale(S)	24,007	$65.23	$1,566,013	Indirect
Nov 18, 2025	BBIO BridgeBio Pharma, Inc.	Sale(S)	30,993	$66.05	$2,047,057	Indirect
Nov 17, 2025	BBIO BridgeBio Pharma, Inc.	Sale(S)	36,801	$66.63	$2,451,914	Direct
Nov 17, 2025	BBIO BridgeBio Pharma, Inc.	Sale(S)	3,798	$67.06	$254,679	Direct
Jun 20, 2025	BBIO BridgeBio Pharma, Inc.	Award(A)	6,589	-	-	Direct
Jun 12, 2025	ABCL AbCellera Biologics Inc.	Award(A) Share option (right to buy)	238,864	-	-	Direct
May 2, 2025	BBIO BridgeBio Pharma, Inc.	Sale(S)	100,000	$38.50	$3,849,900	Indirect

1-8 of 8 transactions

About Lo Andrew

Lo Andrew (SEC CIK 0001679076) files insider reports with the SEC as Director of BridgeBio Pharma, Inc. (BBIO) and Director of AbCellera Biologics Inc. (ABCL).

Signal8 holds 5 ownership filings by Lo Andrew, all Form 4s, filed between May 6, 2025 and Jun 24, 2026. Those filings report 8 transactions, from May 2, 2025 to Jun 22, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Lo Andrew's filings is in PALO ALTO, CA.

Recent filings by Lo Andrew

Jun 22, 2026: Grant or award of BBIO shares (Form 4, code A).
Nov 18, 2025: Open-market sales of BBIO shares (2 lines, Form 4, code S).
Nov 17, 2025: Open-market sales of BBIO shares (2 lines, Form 4, code S).
Jun 20, 2025: Grant or award of BBIO shares (Form 4, code A).
Jun 12, 2025: Grant or award of ABCL derivative securities (Form 4, code A).

Other insiders filing for BridgeBio Pharma, Inc. (BBIO)

Kumar Neil, Chief Executive Officer
Trimarchi Thomas, President and CFO
Apuli Maricel, Chief Accounting Officer
Ellis Andrea, Director
Cook Jennifer E., Director
Valantine Hannah, Director

How to read Form 4 transaction codes